Vaxcyte, Inc.
PCVX· Nasdaq
Released Aug 8, 2023, after the close
10-Q filed Aug 8, 2023, 39 days after period end · 0000950170-23-039817
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$68.34M | -$48.53M | -$23.68M | -$20.32M |
| EPS Diluted | -$0.70 | -$0.80 | -$0.46 | -$1.72 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR